In Vitro Antiretroviral Activity and In Vitro Toxicity Profile of SPD754, a New Deoxycytidine Nucleoside Reverse Transcriptase Inhibitor for Treatment of Human Immunodeficiency Virus Infection

Documenti analoghi

• In Vitro Interactions between Apricitabine and Other Deoxycytidine Analogues
  di: Bethell, R., et al.
  Pubblicazione: (2007)
• Mechanism of Action and In Vitro Activity of 1′,3′-Dioxolanylpurine Nucleoside Analogues against Sensitive and Drug-Resistant Human Immunodeficiency Virus Type 1 Variants
  di: Gu, Zhengxian, et al.
  Pubblicazione: (1999)
• Impact of Nucleoside Reverse Transcriptase Inhibitors on Mitochondria in Human Immunodeficiency Virus Type 1-Infected Children Receiving Highly Active Antiretroviral Therapy
  di: Saitoh, Akihiko, et al.
  Pubblicazione: (2007)
• ATP-Dependent Removal of Nucleoside Reverse Transcriptase Inhibitors by Human Immunodeficiency Virus Type 1 Reverse Transcriptase
  di: Naeger, Lisa K., et al.
  Pubblicazione: (2002)
• Comparison of the Dynamics of Resistance-Associated Mutations to Nucleoside Reverse Transcriptase Inhibitors, Nonnucleoside Reverse Transcriptase Inhibitors, and Protease Inhibitors after Cessation of Antiretroviral Combination Therapy
  di: Wirden, Marc, et al.
  Pubblicazione: (2004)